Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) rather than a periodic financial report.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares (Dividend Re-investment) |
| Share Price | £16.6781 |
| Volume | 1,223.511 shares |
| Transaction Date | July 14, 2016 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records an initial notification of a share acquisition by Ms. E. Walmsley, CEO of GSK Consumer Healthcare, following the re-investment of dividends paid on July 14, 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of a specific insider transaction.
Key Facts for Investor Verification
- Insider Activity: Ms. E. Walmsley (CEO, GSK Consumer Healthcare) acquired 1,223.511 ordinary shares.
- Transaction Nature: The acquisition was not a direct purchase but resulted from the re-investment of dividends.
- Valuation: The transaction occurred at a price of £16.6781 per share on the London Stock Exchange.
- Reporting Scope: This filing does not contain quarterly or annual financial performance data.